Immediate Impact

2 from Science/Nature 57 standout
Sub-graph 1 of 24

Citing Papers

Thyroid Cancer
2024 Standout
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma
2023 Standout
3 intermediate papers

Works of Frederick Millard being referenced

Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma
2014
Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3.
2013
and 1 more

Author Peers

Author Last Decade Papers Cites
Frederick Millard 542 329 245 405 337 45 1.2k
Giorgio Bovo 464 485 293 412 205 62 1.5k
Wei Deng 395 384 281 325 283 87 1.4k
Véronique D’Hondt 329 763 138 287 161 81 1.3k
J. Garcia‐Vargas 401 486 107 494 167 61 1.1k
N. Schleucher 601 789 353 591 160 32 1.6k
Carlyn Tan 417 521 202 284 164 59 1.2k
J J Costanzi 281 635 131 293 187 36 1.2k
Giuseppe Fornarini 524 560 291 224 160 123 1.2k
Terukazu Nakamura 364 346 210 563 156 70 1.3k
Shigeo Aizawa 415 405 314 404 128 56 1.2k

All Works

Loading papers...

Rankless by CCL
2026